Aptahem enters new consortium financed by the KK Foundation
Aptahem (publ) today announce that the company enters a consortium together with Örebro University, Attgeno AB, BioReperia AB, Buzzard Pharmaceuticals AB, Lipum AB, Thermo Fisher Scientific och Toleranzia AB. The newly established consortium aims to evaluate new treatments to reduce inflammation in cardiovascular diseases and breast cancer.The joint research project, titled Drug discovery targeting inflammation – novel therapeutic aspects on vascular inflammation, thrombosis and breast cancer, has obtained financing from the Swedish KK-foundation and will run over a four-year period with